COSCIENS Historical Income Statement

CSCI Stock   3.13  0.04  1.29%   
Historical analysis of COSCIENS Biopharma income statement accounts such as Interest Expense of 89.8 K, Selling General Administrative of 3.7 M or Total Revenue of 9.3 M can show how well COSCIENS Biopharma performed in making a profits. Evaluating COSCIENS Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of COSCIENS Biopharma's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining COSCIENS Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether COSCIENS Biopharma is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

About COSCIENS Income Statement Analysis

COSCIENS Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to COSCIENS Biopharma shareholders. The income statement also shows COSCIENS investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

COSCIENS Biopharma Income Statement Chart

As of now, COSCIENS Biopharma's Research Development is increasing as compared to previous years. The COSCIENS Biopharma's current Reconciled Depreciation is estimated to increase to about 1.6 M, while Tax Provision is forecasted to increase to (855.6 K).

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Total Revenue

Total revenue comprises all receipts COSCIENS Biopharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from COSCIENS Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of COSCIENS Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on COSCIENS Biopharma income statement and represents the costs associated with goods and services COSCIENS Biopharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from COSCIENS Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into COSCIENS Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.As of now, COSCIENS Biopharma's Research Development is increasing as compared to previous years. The COSCIENS Biopharma's current Reconciled Depreciation is estimated to increase to about 1.6 M, while Tax Provision is forecasted to increase to (855.6 K).
 2021 2022 2023 2024 (projected)
Gross Profit8.2M8.1M3.0M5.1M
Total Revenue13.5M13.9M7.3M9.3M

COSCIENS Biopharma income statement Correlations

Click cells to compare fundamentals

COSCIENS Biopharma Account Relationship Matchups

Currently Active Assets on Macroaxis

When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.69)
Revenue Per Share
3.759
Quarterly Revenue Growth
0.041
Return On Assets
(0.23)
Return On Equity
(0.66)
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.